NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Terremoto Biosciences

Terremoto Biosciences

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://terremotobio.com/

Last Round

Series C

Apr 15, 2026

Total Funding Raised

$358M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Terremoto Biosciences is a biotechnology company that develops a drug delivery and discovery platform for small-molecule medicines, enabling the creation of therapies with enhanced clinical profiles and improved therapeutic benefits for serious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small molecule therapeuticsAKT1 inhibitordrug discoveryoncologybiotechselective inhibitorclinical-stage biotechtargeted therapystructure-based designcovalent dockinghereditary diseaseFDA fast trackdrug pipelinebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Terremoto Biosciences Comps

Public and private peers based on sector, stage, and business model.

Terremoto Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Terremoto Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 15, 2026
Series BNov 2, 2023
Series AMay 25, 2022

Key People

Founding team and executive leadership

Charles Baum

CEO and Board Member

Executive Team

Terremoto Biosciences Investors

Notable investors and investment history

Terremoto Biosciences investors
InvestorRounds
EcoR1 CapitalSeries B
RA Capital ManagementSeries C
Cormorant Asset ManagementSeries C, Series B
Deep Track CapitalSeries C
Osage University PartnersSeries C
OrbiMedSeries C, Series B, Series A
Cormorant CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    $108M round completed.

  • Jan 10, 2025

    James Christensen appointed President and Head of Research & Development.

Terremoto Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Terremoto Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Terremoto Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range50
Year Founded2021
Last FundingApr 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.